Immunomodulatory effects of sorafenib on peripheral immune effector cells in ... - UroToday Print
UroToday
Tyrosine kinase inhibitors (TKI) such as sorafenib have substantially improved the prognosis of metastatic renal cell carcinoma (mRCC) patients,

...